

11, 16, and 19 of the Federal Reserve Act, 12 U.S.C. 248(i), 248–1, 464). The obligation to respond is required for the institution to obtain the benefit of an increase in daylight overdraft capacity beyond the limit afforded by the exempt-from-filing cap. The Board has confirmed that the disclosure of information collected on the FR 2226 would likely cause substantial harm to the competitive position of the respondent institution. Therefore, the FR 2226 is exempt from disclosure under exemption (b)(4) of the Freedom of Information Act (FOIA), which exempts from disclosure “trade secrets and commercial or financial information obtained from a person and privileged or confidential.” (5 U.S.C. 552(b)(4)). In addition, information reported in connection with the second and third resolutions may be protected under section (b)(8) of FOIA, to the extent that such information is based on the institution’s CAMELS rating, and thus is related to examination reports prepared by, on behalf of, or for the use of an agency responsible for the regulation or supervision of financial institutions. (5 U.S.C. 552(b)(8)).

4. Report title: Ad Hoc Payments Survey (FR 3054a), Currency Quality Sampling Survey (FR 3054b), Currency Quality Survey (FR 3054c), and Currency Functionality and Perception Survey (FR 3054d).

Agency form number: FR 3054a, FR 3054b, FR 3054c, and FR 3054d.

OMB control number: 7100–0332

Frequency: FR 3054a, annually; FR 3054b, annually; FR 3054c, semi-annually; and FR 3054d, quarterly.

Respondents: Financial, institutions (or depository institutions) individuals, law enforcement and nonfinancial businesses (banknote equipment manufacturers, or global wholesale bank note dealers).

Estimated number of respondents: FR 3054a, 20,000 respondents; FR 3054b, 300 respondents; FR 3054c, 25 respondents; and FR 3054d, 250 respondents.

Estimated average hours per response: FR 3054a, 0.75 hours; FR 3054b, 0.50 hours; FR 3054c, 30 hours; and FR 3054d, 2.50 hours.

Estimated annual burden hours: FR 3054a, 15,000 hours; FR 3054b, 150 hours; FR 3054c, 1,500 hours; and FR 3054d, 2,500 hours.

General Description of Report: The FR 3054a is an event-driven survey used to obtain information specifically tailored to the Federal Reserve’s operational and fiscal agency responsibilities. The FR 3054a may be conducted independently

by the Board or jointly with another government agency, a Reserve Bank, or a private firm. The FR 3054b is an annual survey used to assess the quality of currency in circulation and may be conducted by the Federal Reserve Board, jointly with the Federal Reserve Bank of San Francisco’s Cash Product Office (CPO), the Federal Reserve Bank of Richmond’s Currency Technology Office (CTO), and each Reserve Bank’s cash department. The FR 3054c is a semiannual survey used to determine depository institutions’ and Banknote Equipment Manufacturers’ (BEMs) opinions of currency quality and may be conducted jointly with the CPO and CTO. The FR 3054d is an annual survey used to assess the functionality of Federal Reserve notes in bank-note handling equipment. The data collected from the FR 3054d are used as inputs for future designs of Federal Reserve notes. The FR 3054d may be conducted jointly with the U.S. Treasury’s Bureau of Engraving and Printing (BEP) and the CTO. The FR 3054a, FR 3054b, FR 3054c, and FR 3054d are sent to financial and nonfinancial businesses.

The Federal Reserve Board may use the data collected from these surveys to determine (1) demand for currency and coin, (2) market preferences regarding currency quality, (3) quality of currency in circulation, (4) features used by the public and bank note authentication equipment to denominate and authenticate bank notes, and (5) whether changes to Reserve Bank sorting algorithms are necessary to ensure that currency in circulation remains fit for commerce.

Legal authorization and confidentiality: The Board’s Legal Division has determined that section 11(d) of the Federal Reserve Act (12 U.S.C. 248(d)) authorizes the Board to “supervise and regulate through the Secretary of the Treasury the issue and retirement of Federal reserve notes, except for the cancellation and destruction, and accounting with respect to such cancellation and destruction, of notes unfit for circulation, and to prescribe rules and regulations under which such notes may be delivered by the Secretary of the Treasury to the Federal Reserve agents applying therefor.” This provision of the Federal Reserve Act provides the legal authorization for this information collection. The obligation to respond to the FR 3054a, FR 3054b, FR 3054c, and FR 3054d is voluntary.

Because survey questions may differ from survey to survey, it is difficult to determine in advance whether the

information collected will be considered confidential. However, information may be exempt from disclosure under exemption 4 of the Freedom of Information Act, 5 U.S.C. 552(b)(4), if disclosure would likely have the effect of (1) impairing the government’s ability to obtain the necessary information in the future, or (2) causing substantial harm to the competitive position of the respondent. Additionally, should survey responses contain any information of a private nature the disclosure of which would constitute “a clearly unwarranted invasion of personal privacy,” such information may be exempt from disclosure under exemption 6, 5 U.S.C. 552(b)(6). Confidentiality matters should be treated on a case-by-case basis to determine if any of the above exemptions apply.

Board of Governors of the Federal Reserve System, February 7, 2017.

Robert deV. Frierson,
Secretary of the Board.

[FR Doc. 2017–02827 Filed 2–10–17; 8:45 am]

BILLING CODE 6210–01–P

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination—on the dates indicated—of the waiting period provided by law and the premerger notification rules. The listing for each transaction includes the transaction number and the parties to the transaction. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

EARLY TERMINATIONS GRANTED JANUARY 1, 2017 THRU JANUARY 31, 2017

01/03/2017

20170451	G	IIF US Holding LP; United States Power Fund III, L.P.; IIF US Holding LP.
20170459	G	Asbury Automotive Group, Inc.; David and Jackie Cox; Asbury Automotive Group, Inc.
20170467	G	Synchronoss Technologies, Inc.; IntraLinks Holdings, Inc.; Synchronoss Technologies, Inc.
20170474	G	Desmarais Family Residuary Trust; Performance Sports Group Ltd.; Desmarais Family Residuary Trust.
20170475	G	Fairfax Financial Holdings Limited; Performance Sports Group Ltd.; Fairfax Financial Holdings Limited.
20170477	G	West Street Capital Partners VII, L.P.; The Goldman Sachs Group, Inc.; West Street Capital Partners VII, L.P.
20170478	G	West Street Capital Partners VII, L.P.; Altor Holding AB; West Street Capital Partners VII, L.P.
20170479	G	Sterling Investment Partners III, L.P.; Belnick, Inc.; Sterling Investment Partners III, L.P.
20170482	G	Quantum Energy Partners V, LP; Gulfport Energy Corporation; Quantum Energy Partners V, LP.
20170484	G	Sumitomo Corporation; Fyffes plc; Sumitomo Corporation.
20170490	G	LSF9 Pharaoh L.P.; Halmont Properties Corporation; LSF9 Pharaoh L.P.
20170491	G	The Hearst Family Trust; David L. Morgan and Milleson M. Morgan; The Hearst Family Trust.
20170493	G	Nucor Corporation; San Faustin N.V.; Nucor Corporation.
20170500	G	TPG Partners VII, L.P.; Thoma Bravo Fund X, L.P.; TPG Partners VII, L.P.
20170506	G	John B. Zachry; Ambitech Engineering Corporation; John B. Zachry.

01/04/2017

20170426	G	China Reform Holdings Corporation Ltd.; Lattice Semiconductor Corporation; China Reform Holdings Corporation Ltd.
20170487	G	Sika AG; Linda W. Hart and Milledge A. Hart, III; Sika AG.
20170497	G	Sibanye Gold Limited; Stillwater Mining Company; Sibanye Gold Limited.
20170501	G	BCP Energy Services Fund, LP; Charles E. Price; BCP Energy Services Fund, LP.

01/06/2017

20170432	G	TCV VIII, L.P.; Payoneer Inc.; TCV VIII, L.P.
20170468	G	Greenlight Capital, L.P.; General Motors Company; Greenlight Capital, L.P.
20170469	G	Greenlight Capital (Gold), L.P.; General Motors Company; Greenlight Capital (Gold), L.P.
20170470	G	Greenlight Capital Re, Ltd.; General Motors Company; Greenlight Capital Re, Ltd.
20170471	G	Greenlight Capital Offshore (Gold), Ltd.; General Motors Company; Greenlight Capital Offshore (Gold), Ltd.
20170472	G	Greenlight Capital Qualified, L.P.; General Motors Company; Greenlight Capital Qualified, L.P.
20170473	G	Greenlight Capital Offshore, Ltd.; General Motors Company; Greenlight Capital Offshore, Ltd.
20170483	G	NWP HoldCo LLC; Sociedade de Gestao e Financiamentos, S.G.P.S., S.A.; NWP HoldCo LLC.
20170494	G	KSBP Holdings, LLC; Kendra Scott; KSBP Holdings, LLC.
20170522	G	Pamlico Capital III, L.P.; LOE Holdings, LLC; Pamlico Capital III, L.P.
20170528	G	Intel Corporation; There Holding B.V.; Intel Corporation.
20170530	G	Bain Capital Fund XI, L.P.; Epic/Freedom, LLC; Bain Capital Fund XI, L.P.

01/09/2017

20170517	G	Netmarble Games Corporation; Kabam, Inc.; Netmarble Games Corporation.
20170525	G	Liberty Mutual Holding Company Inc.; GUO GUANGCHANG; Liberty Mutual Holding Company Inc.
20170529	G	KKR European Fund IV L.P.; Gfk Verein; KKR European Fund IV L.P.

01/10/2017

20170460	G	H.I.G. Middle Market LBO Fund II, L.P.; Lionbridge Technologies, Inc.; H.I.G. Middle Market LBO Fund II, L.P.
20170502	G	Global Atlantic Financial Group Limited; Perella Weinberg Partners ABV Opportunity Master Fund III B; Global Atlantic Financial Group Limited.
20170507	G	Casablanca Holdings L.P.; Bain Capital Fund X, L.P.; Casablanca Holdings L.P.
20170511	G	New Mountain Partners IV, L.P.; Dr. Barry Arkles; New Mountain Partners IV, L.P.

01/11/2017

20170439	G	Consolidated Communications Holdings, Inc.; FairPoint Communications, Inc.; Consolidated.
20170513	G	Communications Holdings, Inc. Munksjo Oyj; Ahlstrom Corporation; Munksjo Oyj.

01/12/2017

20170458	G	Novartis AG; Ziarc Group Limited; Novartis AG.
20170496	G	Novartis AG; Encore Vision, Inc.; Novartis AG.
20170527	G	WerfenLife, S.A.; Warburg Pincus Private Equity X, L.P.; WerfenLife, S.A.

01/13/2017

20170488	G	Gemalto N.V.; 3M Company; Gemalto N.V.
20170533	G	Patterson-UTI Energy, Inc.; Seventy Seven Energy Inc.; Patterson-UTI Energy, Inc.
20170535	G	Welsh Carson Anderson & Stowe XI, LP; Revel Systems, Inc.; Welsh Carson Anderson & Stowe XI, LP.
20170536	G	AIF VIII Euro Holdings, L.P.; Koninklijke Philips N.V.; AIF VIII Euro Holdings, L.P.
20170538	G	Alta Resources Development, LLC; Anadarko Petroleum Corporation; Alta Resources Development, LLC.
20170549	G	Vulcan Materials Company; Jack D. Lowery and Susannah S. Lowery; Vulcan Materials Company.
20170552	G	Alta Resources Development, LLC; Mitsui & Co. Ltd.; Alta Resources Development, LLC.

EARLY TERMINATIONS GRANTED JANUARY 1, 2017 THRU JANUARY 31, 2017—Continued

20170554	G	Warburg Pincus Private Equity XII, L.P.; A&M Capital Partners, LP; Warburg Pincus Private Equity XII, L.P.
20170555	G	Gee Automotive Holdings, LLC; Edward C. Tonkin; Gee Automotive Holdings, LLC.
20170557	G	Gee Automotive Holdings, LLC; Bradley E. Tonkin; Gee Automotive Holdings, LLC.

01/17/2017

20170461	G	Schweitzer-Manduit International, Inc.; Leucadia National Corporation; Schweitzer-Manduit International, Inc.
20170466	G	Warburg Pincus Private Equity XI, L.P.; Minnesota Mutual Companies, Inc.; Warburg Pincus Private Equity XI, L.P.
20170518	G	Golden Gate Capital Opportunity Fund, L.P.; NeuStar, Inc.; Golden Gate Capital Opportunity Fund, L.P.
20170542	G	Partners Group Client Access 19, L.P. Inc.; Quad-C Partners VII, L.P.; Partners Group Client Access 19, L.P. Inc.
20170547	G	MMJS Trust; Apache Industrial Holdings, Inc.; MMJS Trust.
20170551	G	Lonza Group Ltd; CH Holding L.P.; Lonza Group Ltd.
20170558	G	Thoma Bravo Fund XII, L.P.; PHNTM Holdings, Inc.; Thoma Bravo Fund XII, L.P.

01/18/2017

20170464	G	Sierra Private Investments L.P.; Mitel Networks Corporation; Sierra Private Investments L.P.
20170495	G	KKR North America Fund, XI, L.P.; Blackstone Capital Partners VI L.P.; KKR North America Fund, XI, L.P.

01/19/2017

20170520	G	Unilever N.V.; Living Proof, Inc.; Unilever N.V.
20170543	G	Prestige Brands Holdings, Inc.; C.B. Fleet TopCo, LLC; Prestige Brands Holdings, Inc.

01/23/2017

20170553	G	Altor Holding AB; Transcom Worldwide AB; Altor Holding AB.
20170556	G	Berkshire Hathaway Inc.; Schulz Holding GmbH & Co. KG; Berkshire Hathaway Inc.
20170564	G	Secondary Opportunities Fund III, LP; Enhanced Equity Fund, L.P.; Secondary Opportunities Fund III, LP.
20170565	G	Secondary Opportunities Fund III, LP; Enhanced Equity Fund II, L.P.; Secondary Opportunities Fund III, LP.
20170566	G	Atlassian Corporation Plc; Trello, Inc.; Atlassian Corporation Plc.
20170570	G	Blackstone Core Equity Partners L.P.; RT SESAC Holdings LP; Blackstone Core Equity Partners L.P.
20170572	G	Hennessy Capital Acquisition Corp. II; Daseke, Inc.; Hennessy Capital Acquisition Corp. II.
20170574	G	LTR Group Holdings, LLC; Clearlake Capital Partners IV (AIV-Atlas), L.P.; LTR Group Holdings, LLC.
20170583	G	Svenska Cellulosa Aktiebolaget SCA; EQT VI (No.1) Limited Partnership; Svenska Cellulosa Aktiebolaget SCA.
20170589	G	Bain Capital Fund XI, L.P.; J.H. Whitney VII, L.P.; Bain Capital Fund XI, L.P.
20170590	G	J.H. Whitney VII, L.P.; Bain Capital Fund XI, L.P.; J.H. Whitney VII, L.P.

01/24/2017

20170584	G	KKR Asian Fund II Japan AIV L.P.; Hitachi, Ltd.; KKR Asian Fund II Japan AIV L.P.
----------------	---	---

01/25/2017

20170514	G	Insight MB Holdings, LLC; Riverside Micro-Cap Fund II, L.P.; Insight MB Holdings, LLC.
20170532	G	Visa Inc.; CardinalCommerce Corporation; Visa Inc.
20170563	G	Allergan plc; Chiron Guernsey Holdings L.P. Inc.; Allergan plc.
20170571	G	Assurant, Inc.; Walter Investment Management Corp.; Assurant, Inc.
20170576	G	Celgene Corporation; Delinia, Inc.; Celgene Corporation.
20170578	G	Jorge Paulo Lemann; Agnaten SE; Jorge Paulo Lemann.
20170579	G	Eugenie Patri Sabastien EPS, SA; Agnaten SE; Eugenie Patri Sabastien EPS, SA.

01/26/2017

20170523	G	First Horizon National Corporation; Coastal Financial Holdings, Inc.; First Horizon National Corporation.
----------------	---	---

01/27/2017

20170334	G	Oracle Corporation; Dynamic Network Services Inc.; Oracle Corporation.
20170454	G	CHRISTUS Health; Good Shepherd Health System, Inc.; CHRISTUS Health.
20170595	G	LSF X International 2, L.P.; Arclin Cayman Holdings Ltd.; LSF X International 2, L.P.
20170597	G	Fairfax Financial Holdings Limited; Allied World Assurance Company Holdings, AG; Fairfax Financial Holdings Limited.
20170606	G	Nippon Paint Holdings Co., Ltd.; DE Parent Corp.; Nippon Paint Holdings Co., Ltd.

01/30/2017

20170618	G	L Catterton VIII, L.P.; Leslie's Holdings, Inc.; L Catterton VIII, L.P.
20170621	G	Ulysses L. Bridgeman, Jr.; The Coca-Cola Company; Ulysses L. Bridgeman, Jr.
20170639	G	Takeda Pharmaceutical Company Limited; ARIAD Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited.

01/31/2017

20170540	G	ArcLight Energy Partners Fund VI, L.P.; Lindsay Goldberg III AIV L.P.; ArcLight Energy Partners Fund.
20170581	G	VI, L.P. Monomoy Capital Partners II, L.P.; Corinthian Equity Fund, L.P.; Monomoy Capital Partners II, L.P.

FOR FURTHER INFORMATION CONTACT:

Theresa Kingsberry, Program Support Specialist, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room CC-5301, Washington, DC 20024, (202) 326-3100.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 2017-02892 Filed 2-10-17; 8:45 am]

BILLING CODE 6750-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Agency for Healthcare Research and Quality, HHS.

ACTION: Notice.

SUMMARY: This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the proposed information collection project “*The Re-Engineered Visit for Primary Care (AHRQ REV)*.” In accordance with the Paperwork Reduction Act, AHRQ invites the public to comment on this proposed information collection.

DATES: Comments on this notice must be received by April 14, 2017.

ADDRESSES: Written comments should be submitted to: Doris Lefkowitz, Reports Clearance Officer, AHRQ, by email at doris.lefkowitz@AHRQ.hhs.gov.

Copies of the proposed collection plans, data collection instruments, and specific details on the estimated burden can be obtained from the AHRQ Reports Clearance Officer.

FOR FURTHER INFORMATION CONTACT:

Doris Lefkowitz, AHRQ Reports Clearance Officer, (301) 427-1477, or by emails at doris.lefkowitz@AHRQ.hhs.gov.

SUPPLEMENTARY INFORMATION:**Proposed Project**

The Re-Engineered Visit for Primary Care (AHRQ REV)

This project—The Re-engineered Visit for Primary Care (AHRQ REV)—directly addresses the agency’s goal to conduct research to enhance the quality of health care and reduction of avoidable readmissions, which are a major indicator of poor quality and patient safety. Research from AHRQ’s

Healthcare Cost and Utilization Project (HCUP) indicates that in 2011 there were approximately 3.3 million adult hospital readmissions in the United States. Adults covered by Medicare have the highest readmission rate (17.2 per 100 admissions), followed by adults covered by Medicaid (14.6 per 100 admissions) and privately insured adults (8.7 per 100 admissions). High rates of readmissions are a major patient safety problem associated with medical errors such as prescribing errors and misdiagnoses of conditions in the hospital and ambulatory care settings. Collectively these readmissions are associated with \$41.3 billion in annual hospital costs, many of which could potentially be avoided. The post-hospital discharge is a handoff ripe with hazards, potentially leading to an array of adverse events including the development of new or worsening symptoms, unplanned readmissions, and increased costs.

In recent years, payer and provider efforts to reduce readmissions have proliferated. Many of these national programs have been informed or guided by evidence-based research, toolkits and guides, such as AHRQ’s RED (Re-Engineered Discharge), STAAR (State Action on Avoidable Readmission), AHRQ’s Project BOOST (Better Outcomes by Optimizing Safe Transitions), the Hospital Guide to Reducing Medicaid Readmissions, and Eric Coleman’s Care Transitions Intervention. These efforts have largely focused on enhancing practices occurring within the hospital setting, including the discharge process and handoffs to receiving providers or settings of care. While many of these efforts have recognized the critical role of primary care in managing care transitions, they have not had an explicit focus on enhancing primary care with the aim of reducing avoidable readmissions.

Evidence-based guidance for the primary care setting to reduce readmissions and improve patient safety are comparatively lacking, and this gap in the literature is becoming more pronounced as primary care is increasingly being called to serve as the key integrator role across the health system as part of payment and delivery system reforms. This research project aims to address the important and unfulfilled need to improve patient safety and reduce avoidable readmissions within the primary care context.

AHRQ’s goals in supporting this 30-month project are to build on the knowledge base from the inpatient settings, add to the expanding evidence

base on preventing readmissions by focusing on the primary care setting, and provide insight on the components and themes that should be part of a re-engineered visit in primary care that will ultimately inform an effective intervention that can be tested in a diverse set of primary care clinics.

To meet AHRQ’s goals and objectives, the agency awarded a task order to John Snow, Inc. (JSI) to conduct a combination of qualitative research and quality improvement techniques to investigate the primary care-based transitional care workflow from the primary care staff, patient, and community agency perspective.

This research has the following goals:

1. Analyze current processes in the primary care visit associated with hospital discharge; and

2. Identify components of the re-engineered visit.

This study is being conducted by AHRQ through its contractor pursuant to AHRQ’s statutory authority to conduct and support research on health care and on systems for the delivery of such care, including activities with respect to the quality, effectiveness, efficiency, appropriateness and value of health care services and with respect to quality measurement and improvement. 42 U.S.C. 299a(a)(1) and (2).

Method of Collection

To analyze current processes in the primary care visit associated with hospital discharge, the data collection has separated into seven smaller data collection activities to minimize research participant burden while still allowing for the collection of necessary data. Each of these tasks will be conducted at nine primary care sites:

1. Primary care site organizational characteristics survey: The purpose of this background information on the primary care site’s organizational characteristics is to offer context for the work flow mapping. It will help make the work flow mapping process more efficient and reduce burden by only requesting information that is already known by a site contact at each of the nine primary care practices. One person per primary care site will be engaged for this task.

2. Primary care site patient characteristics survey: The purpose of this background information on the primary care site’s patients is to offer context for the work flow mapping. It will help make the work flow mapping process more efficient and reduce burden by only requesting information that is already known in the primary care practices’ billing or clinical information systems. One person per